Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SELECTED
LANGUAGE

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors

FDA Approvals in HCC, RCC, and CLL, and ODAC Recommendations

Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors

Liquid Biopsies: Complementary Tool in Detecting Driver Mutations in NSCLC

Meta-Analysis Sheds Light on Treatment-Related AEs for PD-1 and PD-L1 Inhibitors

Ibrutinib Established as Standard for Older CLL Patients

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

Novel Combination Shows Early Efficacy in Ovarian Cancer

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

Related Videos

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

View Conference Coverage

2019 ASCO Annual Meeting

2019 State of the Science Summit on Genitourinary Cancers in Needham

2019 State of the Science Summit on Hematologic Malignancies in Wisconsin

2019 European Lung Cancer Congress

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma	May 30, 2019	2.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer Conference	May 30, 2019	6.5